Standard

Dexamethasone Effects on Cell Composition and Myelin Content in the Mouse Brain. / Aladev, Stanislav; Sokolov, Dmitry; Politko, Maxim и др.

в: Biocell, Том 49, № 6, 24.06.2025, стр. 1057-1069.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

Aladev, S, Sokolov, D, Politko, M, Kazanskaya, G, Aidagulova, S & Grigorieva, E 2025, 'Dexamethasone Effects on Cell Composition and Myelin Content in the Mouse Brain', Biocell, Том. 49, № 6, стр. 1057-1069. https://doi.org/10.32604/biocell.2025.064100

APA

Aladev, S., Sokolov, D., Politko, M., Kazanskaya, G., Aidagulova, S., & Grigorieva, E. (2025). Dexamethasone Effects on Cell Composition and Myelin Content in the Mouse Brain. Biocell, 49(6), 1057-1069. https://doi.org/10.32604/biocell.2025.064100

Vancouver

Aladev S, Sokolov D, Politko M, Kazanskaya G, Aidagulova S, Grigorieva E. Dexamethasone Effects on Cell Composition and Myelin Content in the Mouse Brain. Biocell. 2025 июнь 24;49(6):1057-1069. doi: 10.32604/biocell.2025.064100

Author

Aladev, Stanislav ; Sokolov, Dmitry ; Politko, Maxim и др. / Dexamethasone Effects on Cell Composition and Myelin Content in the Mouse Brain. в: Biocell. 2025 ; Том 49, № 6. стр. 1057-1069.

BibTeX

@article{28c0fe1936b84fa7a9474a399e6b200e,
title = "Dexamethasone Effects on Cell Composition and Myelin Content in the Mouse Brain",
abstract = "Background: Glucocorticoids are used as anti-inflammatory drugs for the treatment of various diseases, however, their side effects on normal brain tissue remain underinvestigated. Objectives: The study aimed to investigate dexamethasone (DXM) effects on cell composition and myelin content in the mouse brain tissue. Methods: C57Bl/6 male mice (n = 60) received single and ten multiple intraperitoneal DXM injections (2.5 mg/kg), and the studied parameters were analysed at 1, 3, 7, 10 days after a single DXM injection and 15, 30, 60, and 90 days after the multiple injections. Oligodendrocytes, microglia, and astrocytes were assayed by immunohistochemistry with specific antibodies (Olig2, CD68, and GFAP, respectively) in the corpus callosum of the normal brain tissue. The myelin content was estimated by staining with LuxolFastBlue. The presence of GFAP isoforms was determined by western blotting. Results: DXM administration did not affect oligodendrocytes in the mouse brain but temporarily significantly decreased myelin content (1.2-fold, p = 0.0058; 1.4-fold, p < 0.0001) at 3–15 days time points. At the same time, DXM significantly decreased the number of microglial cells (1.5–3.5-fold, p < 0.0001) and significantly increased astrocytes (1.8-fold, p < 0.0001). Prolonged administration of DXM resulted in the decrease of the main GFAP α-isoform (50 kDa) and the appearance of shorter GFAP isoforms (30 kDa, 42 kDa, 44 kDa) similar to that in some neurodegenerative animal models. Conclusion: DXM can modify the cell composition of the normal mouse brain tissue by decreasing microglial cells and increasing astrocytes. Long-term use of DXM results in the inhibition of myelin formation and the appearance of truncated GFAP isoforms, suggesting its ability to induce neurodegeneration-like changes in the normal mouse brain.",
keywords = "Glucocorticoid, dexamethasone, oligodendrocyte, myelin basic protein, microglia, astrocyte, glial fibrillary acidic protein (GFAP), mouse model",
author = "Stanislav Aladev and Dmitry Sokolov and Maxim Politko and Galina Kazanskaya and Svetlana Aidagulova and Elvira Grigorieva",
note = "Dexamethasone Effects on Cell Composition and Myelin Content in the Mouse Brain / S. Aladev, D. Sokolov, M. Politko, G. Kazanskaya, S. Aidagulova, E. Grigorieva // Biocell. - 2025. - Т. 46. № 6. - С. 1057-1069. DOI 10.32604/biocell.2025.064100 This research was funded by the budgetary funding to FRC FTM for the project “Post-Genomic High-Tech Research on the Mechanisms of Development of Socially Significant Diseases and Stress-Induced Conditions” (Grant No. 125031203556-7). The authors thank Luydmila Aksenova for the assistance with Western blotting experiments and Tatiana Kotyusheva for performing immunohistochemical staining. The work was performed using the equipment of the Center for Collective Use “Proteomic Analysis”, supported by the Ministry of Science and Higher Education of the Russian Federation (agreement No. 075-15-2021-691).",
year = "2025",
month = jun,
day = "24",
doi = "10.32604/biocell.2025.064100",
language = "English",
volume = "49",
pages = "1057--1069",
journal = "Biocell",
issn = "1667-5746",
publisher = "Tech Science Press",
number = "6",

}

RIS

TY - JOUR

T1 - Dexamethasone Effects on Cell Composition and Myelin Content in the Mouse Brain

AU - Aladev, Stanislav

AU - Sokolov, Dmitry

AU - Politko, Maxim

AU - Kazanskaya, Galina

AU - Aidagulova, Svetlana

AU - Grigorieva, Elvira

N1 - Dexamethasone Effects on Cell Composition and Myelin Content in the Mouse Brain / S. Aladev, D. Sokolov, M. Politko, G. Kazanskaya, S. Aidagulova, E. Grigorieva // Biocell. - 2025. - Т. 46. № 6. - С. 1057-1069. DOI 10.32604/biocell.2025.064100 This research was funded by the budgetary funding to FRC FTM for the project “Post-Genomic High-Tech Research on the Mechanisms of Development of Socially Significant Diseases and Stress-Induced Conditions” (Grant No. 125031203556-7). The authors thank Luydmila Aksenova for the assistance with Western blotting experiments and Tatiana Kotyusheva for performing immunohistochemical staining. The work was performed using the equipment of the Center for Collective Use “Proteomic Analysis”, supported by the Ministry of Science and Higher Education of the Russian Federation (agreement No. 075-15-2021-691).

PY - 2025/6/24

Y1 - 2025/6/24

N2 - Background: Glucocorticoids are used as anti-inflammatory drugs for the treatment of various diseases, however, their side effects on normal brain tissue remain underinvestigated. Objectives: The study aimed to investigate dexamethasone (DXM) effects on cell composition and myelin content in the mouse brain tissue. Methods: C57Bl/6 male mice (n = 60) received single and ten multiple intraperitoneal DXM injections (2.5 mg/kg), and the studied parameters were analysed at 1, 3, 7, 10 days after a single DXM injection and 15, 30, 60, and 90 days after the multiple injections. Oligodendrocytes, microglia, and astrocytes were assayed by immunohistochemistry with specific antibodies (Olig2, CD68, and GFAP, respectively) in the corpus callosum of the normal brain tissue. The myelin content was estimated by staining with LuxolFastBlue. The presence of GFAP isoforms was determined by western blotting. Results: DXM administration did not affect oligodendrocytes in the mouse brain but temporarily significantly decreased myelin content (1.2-fold, p = 0.0058; 1.4-fold, p < 0.0001) at 3–15 days time points. At the same time, DXM significantly decreased the number of microglial cells (1.5–3.5-fold, p < 0.0001) and significantly increased astrocytes (1.8-fold, p < 0.0001). Prolonged administration of DXM resulted in the decrease of the main GFAP α-isoform (50 kDa) and the appearance of shorter GFAP isoforms (30 kDa, 42 kDa, 44 kDa) similar to that in some neurodegenerative animal models. Conclusion: DXM can modify the cell composition of the normal mouse brain tissue by decreasing microglial cells and increasing astrocytes. Long-term use of DXM results in the inhibition of myelin formation and the appearance of truncated GFAP isoforms, suggesting its ability to induce neurodegeneration-like changes in the normal mouse brain.

AB - Background: Glucocorticoids are used as anti-inflammatory drugs for the treatment of various diseases, however, their side effects on normal brain tissue remain underinvestigated. Objectives: The study aimed to investigate dexamethasone (DXM) effects on cell composition and myelin content in the mouse brain tissue. Methods: C57Bl/6 male mice (n = 60) received single and ten multiple intraperitoneal DXM injections (2.5 mg/kg), and the studied parameters were analysed at 1, 3, 7, 10 days after a single DXM injection and 15, 30, 60, and 90 days after the multiple injections. Oligodendrocytes, microglia, and astrocytes were assayed by immunohistochemistry with specific antibodies (Olig2, CD68, and GFAP, respectively) in the corpus callosum of the normal brain tissue. The myelin content was estimated by staining with LuxolFastBlue. The presence of GFAP isoforms was determined by western blotting. Results: DXM administration did not affect oligodendrocytes in the mouse brain but temporarily significantly decreased myelin content (1.2-fold, p = 0.0058; 1.4-fold, p < 0.0001) at 3–15 days time points. At the same time, DXM significantly decreased the number of microglial cells (1.5–3.5-fold, p < 0.0001) and significantly increased astrocytes (1.8-fold, p < 0.0001). Prolonged administration of DXM resulted in the decrease of the main GFAP α-isoform (50 kDa) and the appearance of shorter GFAP isoforms (30 kDa, 42 kDa, 44 kDa) similar to that in some neurodegenerative animal models. Conclusion: DXM can modify the cell composition of the normal mouse brain tissue by decreasing microglial cells and increasing astrocytes. Long-term use of DXM results in the inhibition of myelin formation and the appearance of truncated GFAP isoforms, suggesting its ability to induce neurodegeneration-like changes in the normal mouse brain.

KW - Glucocorticoid

KW - dexamethasone

KW - oligodendrocyte

KW - myelin basic protein

KW - microglia

KW - astrocyte

KW - glial fibrillary acidic protein (GFAP)

KW - mouse model

UR - https://www.scopus.com/pages/publications/105049117722

UR - https://www.mendeley.com/catalogue/edfa946d-f7f7-3544-94e6-96a1baf55a37/

U2 - 10.32604/biocell.2025.064100

DO - 10.32604/biocell.2025.064100

M3 - Article

VL - 49

SP - 1057

EP - 1069

JO - Biocell

JF - Biocell

SN - 1667-5746

IS - 6

ER -

ID: 71528827